Phaseline

Targets › HSV2

HSV2: drug programs, companies and trials

2 programs from 2 companies in 2 trials: 1 Phase 4, 1 Phase 1; Immunology, Infectious disease; next expected readout Apr 2027.

Open in Phaseline: the race on HSV2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
University of Sao Paulo General HospitalAcyclovir
Human herpesvirus 1 DNA polymerase inhibitor
HSV1, HSV2, VZVPhase 4Autoimmune Rheumatic DiseasesApr 2027
BioNTech SEBNT163
Anti-viral RNA vaccine for active immunization against HSV-2
HSV2Phase 1Genital Herpes Simplex Type 2–

Conditions

Autoimmune Rheumatic Diseases (1) Genital Herpes Simplex Type 2 (1)

Modalities

small molecule (1), protein or peptide (1)

Companies

University of Sao Paulo General Hospital (1) BioNTech SE (1)

Related targets

HSV1 (1) VZV (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.